Immunoscintigraphy with131I-labelled monoclonal antibodies HMFG2 and HMFG1 F(ab')2 versus abdominal CT scan in the detection of residual disease in ovarian cancer patients

Pectasides, Dimitrios; Pateniotis, K.; Tzimis, L; Trapalli, X.; Natsis, P.; Arapantoni, P.; Taylor‐Papadimitriou, Joyce; Epenetos, Agamemnon A.; Koutsiouba, P.; Athanassiou, Athanassios

doi:10.1002/ijc.2910410817

Cited by 16 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunoscintigraphy with radiolabeled HMFG1 and HMFG2, an antibody similar to HMFG1 directed to MUC1, successfully detected MUC1 positive tumors in patients with primary and metastatic lesions of ovarian, breast and gastrointestinal cancer with minor adverse events (99)(100)(101)(102)(103)(104). The therapeutic application of radiolabeled HMFG1 in ovarian cancer has been mainly studied following ip administration.…”

Section: Muc1mentioning

confidence: 99%

The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review)

Oei

Sweep²,

Thomas³

et al. 1992

Int J Oncol

View full text Add to dashboard Cite

Abstract.The prognosis for patients with ovarian cancer is still poor and more effective therapeutic modalities are needed. (Radio)immunotherapy using monoclonal antibodies (Mabs) could be one of these approaches. Here, we review the status of (radio)immunotherapy using Mabs for the treatment of ovarian cancer. The Pubmed database was searched for clinical trials investigating the effect of (radio)immunotherapy in ovarian cancer published until October 1, 2007. Keywords for the search were: ovarian cancer, monoclonal antibodies, CA 125, gp38, HER2, HMFG, MUC1, TAG 72 and VEGF. A total of 44 trials on immunotherapy with unconjugated Mabs, Mab vaccination and (radio)immunotherapy directed towards the antigens CA 125, gp38, HER2, MUC1, TAG 72 or VEGF in patients with ovarian cancer were found, reviewed and discussed. Out of these trials, 23 studied immunotherapy with unconjugated Mabs, 5 vaccination with Mabs and 16 trials studied (radio)immunotherapy. The lack of large randomized prospective trials with Mabs directed to tumor-associated antigens expressed on ovarian cancer cells preclude any firm conclusion on the potential of Mabs use in the treatment of ovarian cancer. Oregovomab, directed against CA 125, and bevacizumab, targeting VEGF, are two unconjugated Mabs closest to clinical introduction for the treatment of ovarian cancer. Vaccination with Mab ACA 125 seems promising but these findings need to be confirmed in controlled randomized trials. Sole RIT should be investigated with the appropriate radionuclide and a Mab with high affinity for the specific tumor-associated antigen in the appropriate patient group to determine whether it may have a therapeutic effect. Additionally, appending (radio)immunotherapy with anti-TAG 72 or anti-MUC1 to other treatment strategies such as chemotherapy could also be a strategy worthwhile investigating. The potential of Mabs to complement current treatment paradigms, is encouraging and may bring a significant improvement to the overall therapeutic outcomes currently being achieved in ovarian cancer. IntroductionOvarian cancer is the fourth leading cause of cancer-related death in women, and accounts for the highest mortality rate of all gynecological malignancies (1). Its poor prognosis is mainly the result of the clinically occult nature of this disease. The peritoneal cavity in which the ovaries are localized provides a perfect environment for undisturbed subclinical growth. Furthermore, early detection is difficult because of the general asymptomatic presentation of the disease (2). In the majority (68%) of the patients, ovarian cancer is diagnosed with at least extensive abdominal spread (3). Standard treatment for advanced stage ovarian cancer is tumor debulking surgery and adjuvant chemotherapy. Although most ovarian cancers are sensitive to platinumbased chemotherapy, the prognosis remains poor. The 5-year INTERNATIONAL JOURNAL OF ONCOLOGY 32: 1145-1157 The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (Review) Abbreviations: ADCC, anti...

show abstract

Section: Muc1mentioning

confidence: 99%

The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review)

Oei

Sweep²,

Thomas³

et al. 1992

Int J Oncol

View full text Add to dashboard Cite

show abstract

“…High levels of expression of one particular family of mucins, the epithelial sialomucins, have been noted in ovarian, breast, and pancreatic tumors. Monoclonal antibodies (MAbs) directed against these tumor-associated antigens have been useful in detecting lymph-node metastases in breast-cancer patients and residual disease in ovarian-cancer patients after chemotherapy Pectasides et al, 1988).…”

mentioning

confidence: 99%

Expression of the tumor‐associated mucin MUCI in an ovarian tumor cell line

Stern

Palatsides

Kretser

et al. 1992

Intl Journal of Cancer

View full text Add to dashboard Cite

Epithelial sialomucins constitute a family of high-molecular-weight glycoproteins associated with epithelial cell surfaces. Aberrant expression of these molecules has been observed in certain types of human epithelial tumors. Members of the MUC1 family of mucins isolated from different tissue types have been shown to differ in biochemical properties and in immunological reactivity. The polymerase chain reaction (PCR) has been used in a study of the MUC1 mRNA expressed in ovarian tumor cells. The intron/exon structure of the ovarian mucin gene has been examined, the nucleotide sequence of regions of the cDNA 5' and 3' to a central highly repetitive region of the molecule determined and genomic clones for this mucin from the ovarian tumor cell line COLO316 have been isolated and analyzed. The results are compared with the nucleotide sequence data obtained by others for MUC1 cDNA in breast and pancreatic cell lines. With a single nucleotide exception, the splicing pattern and nucleotide sequence obtained from MUC1 mRNA in the ovarian cell line is the same as that of the mRNA found in breast and pancreatic cell lines. However, it appears that the use of alternate splice acceptors for intron I in the ovarian cell line studied here is independent of the specific sequence variation thought to determine splicing of MUC1 in breast tumor cells.

show abstract

“…administration of radiolabeled MoAbs. Although most studies have used the intravenous route, radiolabeled MoAbs have also been administered intraperitoneally or through the lymphatics (6,25). Following administration of a MoAb, the patient is imaged over the next few days either by external gamma camera providing planar anterior and posterior view images or by single photon emission computerized tomography (SPECT), in which the reconstructed images can be obtained through any plane.…”

Section: Monoclonal Antibodies For Radioimmunodetectionmentioning

confidence: 99%

“…Radioimmunoscintigraphy with HMFG2 and HMFG1 F(abAE) 2 fragments was also evaluated with intraperitoneal administration of monoclonal antibodies. In a clinical study, Pectasides et al evaluated 15 patients with epithelial ovarian cancer who had completed chemotherapy and were in complete or partial remission (25). In 3 out of 15 patients the immunoscan failed, because extensive adhesions from the previous surgery prevented MoAb diffusion.…”

Section: Radioimmunodetectio N Of Ovarian Cancermentioning

confidence: 99%

Radioimmunoscintigraphy in Patients with Ovarian Cancer

Kalofonos

2001

Acta Oncologica

View full text Add to dashboard Cite

The use of radiolabeled monoclonal antibodies (MoAbs) has significantly improved the ability to detect tumor antigens, thus improving in vivo tumor diagnosis and treatment. The management of ovarian carcinoma still poses a challenging medical problem. Clinical trials using radioimmunoscintigraphy or a hand-held gamma detection probe intraoperatively were performed in patients with clinical evidence of primary or recurrent ovarian cancer. Immunoscintigraphy of ovarian cancer lesions has been performed mainly with 99mTc, 111In and 123I labeled with HMFG1, HMFG2, OC-125, B72.3, H17E2, OVTL3, MoAb170, Mov18 and other MoAbs. Antibody guided imaging using radioimmunoscintigraphy has demonstrated improved targeting of ovarian cancer, resulting in a highly sensitive and specific method. However, it is not yet known which type of MoAb is the most efficient for radioimmunoscintigraphy. Since these tumors represent a potentially curable disease, radioimmunoscintigraphy could contribute mainly to accurate staging as a supplementary to conventional diagnostic methods, as well as for the localization of active disease after chemotherapy and monitoring for the presence of recurrent disease. Nevertheless, prospective studies in a large number of patients should be undertaken in order to further evaluate the diagnostic contribution of this approach.

show abstract

Immunoscintigraphy with131I-labelled monoclonal antibodies HMFG2 and HMFG1 F(ab')2 versus abdominal CT scan in the detection of residual disease in ovarian cancer patients

Cited by 16 publications

References 12 publications

The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review)

The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review)

Expression of the tumor‐associated mucin MUCI in an ovarian tumor cell line

Radioimmunoscintigraphy in Patients with Ovarian Cancer

Contact Info

Product

Resources

About